Clinical trials: Altitude Edema
Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
ABBV-RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of Diabetic Retinopathy (DR) with and without Center-Involved Diabetic Macular Edema (CI-DME).
- Trial name
- ALTITUDE® (NCT04567550)
- Testing
- ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3
- Where
- 25 sites in United States
- Volunteers
- 139 people
- Sponsor
- AbbVie
High Altitude Pulmonary Hypertension
Inhaled Nitric Oxide for High Amplitude Pulmonary Edema (HAPE)
High Altitude Pulmonary Edema (HAPE) is a critical, non-cardiogenic pulmonary edema that manifests in high-altitude conditions, marked by the rapid onset of symptoms such as dyspnea, cough, frothy sputum, and cyanosis.
- Trial name
- HAPE (NCT06852924)
- Testing
- Nitric Oxide Generation and Delivery System
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Novlead Inc.